Poor mobilization of hematopoietic progenitors needed to support autologous transplantation is a serious clinical problem. We are investigating the role of plerixafor administered in an at risk population to augment successful stem cell collection. OBJECTIVES To determine if plerixafor when administered on the day prior to planned autologous collection on first mobilization attempt in those with a peripheral blood CD34 ≤ 10X106/L will: * increase the number of patients successfully collected in one day * increase the number of patients successfully mobilized on first collection attempt * is cost neutral within a Canadian setting
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
52
Plerixafor will be administered at 23:00 of Day -1 to experimental subjects at a dose of 240 mcg/kg subcutaneously, and possibly repeated the following day
Nonintervention group, no drug will be given, observation only
CancerCare Manitoba
Winnipeg, Manitoba, Canada
To increase the proportion of Poor Mobilizers who after receiving plerixafor are successfully collected in one day. The anticipated proportion increase is from 30%-60%.
Time frame: within 1-2 days after commencing therapy
To increase the proportion of Poor Mobilizers who after receiving plerixafor are successfully collected on first mobilization attempt rather than requiring a second mobilization.
Time frame: After therapy
To describe the kinetics of platelet and neutrophil recovery post ASCT in those treated and not treated with plerixafor
Time frame: After therapy
To examine the immune recovery at day 100 post ASCT in those treated and not treated with plerixafor
Time frame: After therapy
To undertake a pharmacoeconomic evaluation to examine the impact of plerixafor on resource utilization in a population at risk for poor mobilization
Time frame: After therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.